Search Results

There are 7393 results for: content related to: Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses

  1. REVIEW ON CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade

    Addiction Biology

    Volume 12, Issue 3-4, September 2007, Pages: 227–462, Thomas M. Tzschentke

    Version of Record online : 30 JUL 2007, DOI: 10.1111/j.1369-1600.2007.00070.x

  2. Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal

    European Journal of Neuroscience

    Volume 16, Issue 7, October 2002, Pages: 1377–1389, François Frenois, Martine Cador, Stéphanie Caillé, Luis Stinus and Catherine Le Moine

    Version of Record online : 29 OCT 2002, DOI: 10.1046/j.1460-9568.2002.02187.x

  3. You have full text access to this OnlineOpen article
    Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies

    Clinical and Translational Science

    Volume 10, Issue 5, September 2017, Pages: 380–386, BT Gufford, GR Ainslie, JR White Jr, ME Layton, JM Padowski, GM Pollack and MF Paine

    Version of Record online : 23 MAY 2017, DOI: 10.1111/cts.12473

  4. Naloxone—does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose

    Addiction

    Volume 110, Issue 10, October 2015, Pages: 1644–1652, Joanne Neale and John Strang

    Version of Record online : 30 JUL 2015, DOI: 10.1111/add.13027

  5. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database

    Drug and Alcohol Review

    Rebecca McDonald, Øyvind Danielsson Glende, Ola Dale and John Strang

    Version of Record online : 8 JUN 2017, DOI: 10.1111/dar.12571

  6. You have full text access to this OnlineOpen article
    Src-dependent phosphorylation of μ-opioid receptor at Tyr336 modulates opiate withdrawal

    EMBO Molecular Medicine

    Volume 9, Issue 11, November 2017, Pages: 1521–1536, Lei Zhang, Cherkaouia Kibaly, Yu-Jun Wang, Chi Xu, Kyu Young Song, Patrick W McGarrah, Horace H Loh, Jing-Gen Liu and Ping-Yee Law

    Version of Record online : 18 AUG 2017, DOI: 10.15252/emmm.201607324

  7. You have free access to this content
    Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4

    British Journal of Pharmacology

    Volume 173, Issue 5, March 2016, Pages: 856–869, X Wang, Y Zhang, Y Peng, M R Hutchinson, K C Rice, H Yin and L R Watkins

    Version of Record online : 4 FEB 2016, DOI: 10.1111/bph.13394

  8. You have full text access to this OnlineOpen article
    Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study

    Pain Practice

    Volume 16, Issue 5, June 2016, Pages: 580–599, Ralf Baron, Rudolf Likar, Emilio Martin-Mola, Francisco J. Blanco, Lieven Kennes, Matthias Müller, Dietmar Falke and Ilona Steigerwald

    Version of Record online : 12 JUN 2015, DOI: 10.1111/papr.12308

  9. Naloxone rescheduling in Australia: Processes, implementation and challenges with supply of naloxone as a ‘pharmacist only’ over-the-counter medicine

    Drug and Alcohol Review

    Angelo Pricolo and Suzanne Nielsen

    Version of Record online : 27 APR 2017, DOI: 10.1111/dar.12547

  10. Phosphodiesterase inhibition by naloxone augments the inotropic actions of β-adrenergic stimulation

    Acta Anaesthesiologica Scandinavica

    Volume 53, Issue 8, September 2009, Pages: 1043–1051, W. K. PARK, C. H. CHANG, J. E. CHAE, M. H. KIM, Y. L. CHO and D. S. AHN

    Version of Record online : 30 JUN 2009, DOI: 10.1111/j.1399-6576.2009.02023.x

  11. You have full text access to this OnlineOpen article
    Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial

    Pain Practice

    Volume 16, Issue 5, June 2016, Pages: 600–619, Ralf Baron, Jan-Peter Jansen, Andreas Binder, Manuel Pombo-Suarez, Lieven Kennes, Matthias Müller, Dietmar Falke and Ilona Steigerwald

    Version of Record online : 11 NOV 2015, DOI: 10.1111/papr.12361

  12. Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond

    Drug and Alcohol Review

    Volume 34, Issue 4, July 2015, Pages: 404–411, Simon Lenton, Paul Dietze, Anna Olsen, Nicole Wiggins, David McDonald and Carrie Fowlie

    Version of Record online : 1 OCT 2014, DOI: 10.1111/dar.12198

  13. You have full text access to this OnlineOpen article
    Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study

    Addiction

    Rebecca McDonald, Ulrike Lorch, Jo Woodward, Björn Bosse, Helen Dooner, Gill Mundin, Kevin Smith and John Strang

    Version of Record online : 16 NOV 2017, DOI: 10.1111/add.14033

  14. Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience

    The American Journal on Addictions

    Volume 13, Issue S1, May-June 2004, Pages: S42–S66, Leslie Amass, Walter Ling, Thomas E. Freese, Chris Reiber, Jeffrey J. Annon, Allan J. Cohen, Dennis McCarty, Malcolm S. Reid, Lawrence S. Brown Jr., Cynthia Clark, Douglas M. Ziedonis, Jonathan Krejci, Susan Stine, Theresa Winhusen, Greg Brigham, Dean Babcock, Joan A. Muir, Betty J. Buchan and Terry Horton

    Version of Record online : 18 FEB 2010, DOI: 10.1080/10550490490440807

  15. You have free access to this content
    Naloxone for opiate-exposed newborn infants

    Intervention Review

    The Cochrane Library

    Thirimon Moe-Byrne, Jennifer VE Brown and William McGuire

    Published Online : 28 FEB 2013, DOI: 10.1002/14651858.CD003483.pub2

  16. Take-home naloxone to reduce heroin death

    Addiction

    Volume 100, Issue 12, December 2005, Pages: 1823–1831, Catherine T. Baca and Kenneth J. Grant

    Version of Record online : 23 NOV 2005, DOI: 10.1111/j.1360-0443.2005.01259.x

  17. You have free access to this content
    Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 35, Issue s2, August 2012, Pages: 45–51, K. J. FREISE, G. C. NEWBOUND, C. TUDAN and T. P. CLARK

    Version of Record online : 25 JUN 2012, DOI: 10.1111/j.1365-2885.2012.01409.x

  18. Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway

    Synapse

    Volume 66, Issue 8, August 2012, Pages: 694–704, Shu-Husan Chou, Jen-Hsin Kao, Pao-Luh Tao, Ping-Yee Law and Horace H. Loh

    Version of Record online : 30 MAR 2012, DOI: 10.1002/syn.21555

  19. Blood–brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux

    Journal of Pharmaceutical Sciences

    Volume 99, Issue 1, January 2010, Pages: 413–421, Toyofumi Suzuki, Mariko Miyata, Chika Zaima, Takayuki Furuishi, Toshiro Fukami, Fumihiko Kugawa and Kazuo Tomono

    Version of Record online : 15 JUN 2009, DOI: 10.1002/jps.21819

  20. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?

    Addiction

    Volume 111, Issue 4, April 2016, Pages: 574–582, John Strang, Rebecca McDonald, Basak Tas and Ed Day

    Version of Record online : 3 FEB 2016, DOI: 10.1111/add.13209